Biomarkers for immunotherapy in esophageal cancer

Frontiers in Immunology

Immunology

Xuelian Wang¹  Pei Zhang²  Yanan Han³  Xiang Huang³  Ping Wang⁴ 

[1] Department of Oncology and Hematology, Zhongxian People’s Hospital, Chongqing, China;Department of Radiation Oncology, The Fifth Center of the Chinese PLA General Hospital, Beijing, China;Department of Radiation Oncology, The First Center of the Chinese PLA General Hospital, Beijing, China;Department of Urology, Zhongxian People’s Hospital, Chongqing, China;

关键词: esophageal cancer;    immunotherapy;    biomarker;    PD-1/PD-L1;    cancer immunity;   

DOI  :  10.3389/fimmu.2023.1117523

 received in 2022-12-06, accepted in 2023-04-19,  发布年份 2023

来源: Frontiers

【 摘 要 】

The development of immunotherapy, especially immune-checkpoint inhibitors targeting PD-1/PD-L1, has improved the outcomes of patients with esophageal cancer. However, not all population derives benefit from the agents. Recently, kinds of biomarkers were introduced to predict the response to immunotherapy. However, the effects of these reported biomarkers are controversial and many challenges remain. In this review, we aim to summarize the current clinical evidence and provide a comprehensive understanding of the reported biomarkers. We also discuss the limits of the present biomarkers and propose our own opinions on which viewers’ discretion are advised.

【 授权许可】

Unknown   
Copyright © 2023 Wang, Wang, Huang, Han and Zhang